Reactivation of ancestral strains of HIV-1 in the gp120 V3 env region in patients failing antiretroviral therapy and subjected to structured treatment interruption

Virology

Volumn 354, Issue 1, 2006, Pages 35-47

  Silva, Wilson Pereira ^a   Santos, Domingos E M ^a   Leal, Elcio ^a   Brunstein, Adriana ^a   Sucupira, Maria Cecilia A ^a   Sabino, Ester C ^b   Diaz, Ricardo Sobhie ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b FUNDAÇÃO PRÓ SANGUE HEMOCENTRO DE SÃO PAULO   (Brazil)

Author keywords

Antiretroviral resistance; Envelope gene; HIV 1; Structured treatment interruption

Indexed keywords

ANTIRETROVIRUS AGENT; GLYCOPROTEIN GP 120; VIRUS DNA; VIRUS GLYCOPROTEIN;

ARTICLE; BIOASSAY; CD4+ T LYMPHOCYTE; CIRCULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG TREATMENT FAILURE; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR EVOLUTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TREATMENT WITHDRAWAL; VIRUS ACTIVATION; VIRUS ENVELOPE; VIRUS IMMUNITY; VIRUS INHIBITION; VIRUS LOAD; VIRUS REACTIVATION; VIRUS RESISTANCE; VIRUS STRAIN;

AMINO ACID SEQUENCE; ANTI-HIV AGENTS; CLUSTER ANALYSIS; DNA, VIRAL; EVOLUTION, MOLECULAR; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; NUCLEIC ACID HYBRIDIZATION; PEPTIDE FRAGMENTS; POLYMERASE CHAIN REACTION; PROVIRUSES; SELECTION (GENETICS); SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS, DNA; VARIATION (GENETICS);

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33749022485     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2006.04.039     Document Type: Article

References (45)

1. Cheng-Mayer C., Quiroga M., Tung J.W., Dina D., and Levy J.A. Viral determinants of human immunodeficiency virus type 1 T-cell or macrophage tropism, cytopathogenicity, and CD4 antigen modulation. J. Virol. 64 9 (1990) 4390-4398
2. Chesebro B., Nishio J., Perryman S., Cann A., O'Brien W., Chen I.S., and Wehrly K. Identification of human immunodeficiency virus envelope gene sequences influencing viral entry into CD4-positive HeLa cells, T-leukemia cells, and macrophages. J. Virol. 65 11 (1991) 5782-5789
3. Coffin J.M. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267 5197 (1995) 483-489
4. Costa L.J., Mayer A.J., Busch M.P., and Diaz R.S. Evidence for selection of more adapted human immunodeficiency virus type 1 recombinant strains in a dually infected transfusion recipient. Virus Genes 28 3 (2004) 259-572
5. De Jong J.J., De Ronde A., Keulen W., Tersmette M., and Goudsmit J. Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution. J. Virol. 66 11 (1992) 6777-6780
6. Deeks S.G., Wrin T., Liegler T., Hoh R., Hayden M., Barbour J.D., Hellmann N.S., Petropoulos C.J., McCune J.M., Hellerstein M.K., and Grant R.M. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N. Engl. J. Med. 344 7 (2001) 472-480
7. Delwart E.L., Shpaer E.G., Louwagie J., McCutchan F.E., Grez M., Rubsamen-Waigmann H., and Mullins J.I. Genetic relationships determined by a DNA heteroduplex mobility assay: analysis of HIV-1 env genes. Science 262 5137 (1993) 1257-1261
8. Diaz R.S., Sabino E.C., Mayer A., Mosley J.W., and Busch M.P. Dual human immunodeficiency virus type 1 infection and recombination in a dually exposed transfusion recipient. The Transfusion Safety Study Group. J. Virol. 69 6 (1995) 3273-3281
9. Diaz R.S., Sabino E.C., Mayer A., deOliveira C.F., Mosley J.W., and Busch M.P. Lack of dual HIV infection in a transfusion recipient exposed to two seropositive blood components. AIDS Res. Hum. Retrovir. 12 13 (1996) 1291-1295
10. Diaz R.S., Zhang L., Busch M.P., Mosley J.W., and Mayer A. Divergence of HIV-1 quasispecies in an epidemiologic cluster. AIDS 11 4 (1997) 415-422
11. Diaz R.S., De Oliveira C.F., Pardini R., Operskalski E., Mayer A.J., and Busch M.P. HIV type 1 tat gene heteroduplex mobility assay as a tool to establish epidemiologic relationships among HIV type 1-infected individuals. AIDS Res. Hum. Retrovir. 15 13 (1999) 1151-1156
12. Fouchier R.A., Groenink M., Kootstra N.A., Tersmette M., Huisman H.G., Miedema F., and Schuitemaker H. Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J. Virol. 66 5 (1992) 3183-3187
13. Galtier N., Gouy M., and Gautier C. SEAVIEW and PHYLO_WIN: two graphic tools for sequence alignment and molecular phylogeny. Comput. Appl. Biosci. 12 6 (1996) 543-548
14. Goldman N., and Yang Z. A codon-based model of nucleotide substitution for protein-coding DNA sequences. Mol. Biol. Evol. 11 5 (1994) 725-736
15. Goudsmit J., de Ronde A., de Rooij E., and de Boer R. Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and 215. J. Virol. 71 6 (1997) 4479-4484
16. Hendry R.M., Hanson C.V., Bongertz V., Morgado M., Duarte A., Casseb J., Brigido L., Sabino E., Diaz R., and Galvao-Castro B. Immunoreactivity of Brazilian HIV isolates with different V3 motifs. Mem. Inst. Oswaldo Cruz 91 3 (1996) 347-348
17. Ho D.D. HIV-1 dynamics in vivo. J. Biol. Regul. Homeostatic Agents 9 3 (1995) 76-77
18. Kijak G.H., Simon V., Balfe P., Vanderhoeven J., Pampuro S.E., Zala C., Ochoa C., Cahn P., Markowitz M., and Salomon H. Origin of human immunodeficiency virus type 1 quasispecies emerging after antiretroviral treatment interruption in patients with therapeutic failure. J. Virol. 76 14 (2002) 7000-7009
19. Koot M., van 't Wout A.B., Kootstra N.A., de Goede R.E., Tersmette M., and Schuitemaker H. Relation between changes in cellular load, evolution of viral phenotype, and the clonal composition of virus populations in the course of human immunodeficiency virus type 1 infection. J. Infect. Dis. 173 2 (1996) 349-354
20. Larder B.A., and Kemp S.D. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246 4934 (1989) 1155-1158
21. Long E.M., Martin H.L., Kreiss Jr. J.K., Rainwater S.M., Lavreys L., Jackson D.J., Rakwar J., Mandaliya K., and Overbaugh J. Gender differences in HIV-1 diversity at time of infection. Nat. Med. 6 1 (2000) 71-75
22. Maeda Y., Venzon D.J., and Mitsuya H. Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance. J. Infect. Dis. 177 5 (1998) 1207-1213
23. Mansky L.M., and Temin H.M. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J. Virol. 69 8 (1995) 5087-5094
24. Martinez-Picado J., Savara A.V., Shi L., Sutton L., and D'Aquila R.T. Fitness of human immunodeficiency virus type 1 protease inhibitor-selected single mutants. Virology 275 2 (2000) 318-322
25. McNearney T., Hornickova Z., Markham R., Birdwell A., Arens M., Saah A., and Ratner L. Relationship of human immunodeficiency virus type 1 sequence heterogeneity to stage of disease. Proc. Natl. Acad. Sci. U.S.A. 89 21 (1992) 10247-10251
26. Milich L., Margolin B., and Swanstrom R. V3 loop of the human immunodeficiency virus type 1 Env protein: interpreting sequence variability. J. Virol. 67 9 (1993) 5623-5634
27. Miller V., Sabin C., Hertogs K., Bloor S., Martinez-Picado J., D'Aquila R., Larder B., Lutz T., Gute P., Weidmann E., Rabenau H., Phillips A., and Staszewski S. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. AIDS 14 18 (2000) 2857-2867
28. Morgado M.G., Sabino E.C., Shpaer E.G., Bongertz V., Brigido L., Guimaraes M.D., Castilho E.A., Galvao-Castro B., Mullins J.I., Hendry R.M., et al. V3 region polymorphisms in HIV-1 from Brazil: prevalence of subtype B strains divergent from North American/European prototype and detection of subtype F. AIDS Res. Hum. Retrovir. 10 5 (1994) 569-576
29. Nei M. Molecular Evolutionary Genetics (1987), Columbia Univ. Press, New York
30. Nielsen R., and Yang Z. Likelihood models for detecting positively selected amino acid sites and applications to the HIV-1 envelope gene. Genetics 148 3 (1998) 929-936
31. Opgen-Rhein R., Fahmeir L., and Strimmer K. Inference of demographic history from genealogical trees using reversible jump Markov chain Monte Carlo. BMC Evolut. Biol. 5 6 (2005) 1-13
32. Perelson A.S., Neumann A.U., Markowitz M., Leonard J.M., and Ho D.D. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271 5255 (1996) 1582-1586
33. Posada D., and Crandall K.A. MODELTEST: testing the model of DNA substitution. Bioinformatics 14 9 (1998) 817-818
34. Roos M.T., Lange J.M., de Goede R.E., Coutinho R.A., Schellekens P.T., Miedema F., and Tersmette M. Viral phenotype and immune response in primary human immunodeficiency virus type 1 infection. J. Infect. Dis. 165 3 (1992) 427-432
35. Shankarappa R., Margolick J.B., Gange S.J., Rodrigo A.G., Upchurch D., Farzadegan H., Gupta P., Rinaldo C.R., Learn G.H., He X., Huang X.L., and Mullins J.I. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J. Virol. 73 12 (1999) 10489-10502
36. Simmonds P., Balfe P., Peutherer J.F., Ludlam C.A., Bishop J.O., and Brown A.J. Human immunodeficiency virus-infected individuals contain provirus in small numbers of peripheral mononuclear cells and at low copy numbers. J. Virol. 64 2 (1990) 864-872
37. Smith K.Y., Steffens C.M., Truckenbrod A., Landay A., and Al-Harthi L. Immune reconstitution after successful treatment with protease inhibitor-based and protease inhibitor-sparing antiretroviral regimens. J. Acquired Immune Defic. Syndr. 29 5 (2002) 544-545
38. Sucupira M.C., Souza I.E., Costa L.J., Scheinberg M.A., and Diaz R.S. Antiretroviral treatment failure and HIV-1 genotypic resistance in Sao Paulo, Brazil, Antiviral Therapy. Antivir. Ther. 6 4 (2001) 263-264
39. Wei X., Ghosh S.K., Taylor M.E., Johnson V.A., Emini E.A., Deutsch P., Lifson J.D., Bonhoeffer S., Nowak M.A., Hahn B.H., et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373 6510 (1995) 117-122
40. Wolfs T.F., Zwart G., Bakker M., Valk M., Kuiken C.L., and Goudsmit J. Naturally occurring mutations within HIV-1 V3 genomic RNA lead to antigenic variation dependent on a single amino acid substitution. Virology 185 1 (1991) 195-205
41. Wolinsky S.M., Korber B.T., Neumann A.U., Daniels M., Kunstman K.J., Whetsell A.J., Furtado M.R., Cao Y., Ho D.D., and Safrit J.T. Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection. Science 272 5261 (1996) 537-542
42. Yang Z. Phylogenetic Analysis by Maximum Likelihood (PAML), Version 1.4 (1997), Department of Integrative Biology, University of California, Berkeley
43. Zhang L.Q., MacKenzie P., Cleland A., Holmes E.C., Brown A.J., and Simmonds P. Selection for specific sequences in the external envelope protein of human immunodeficiency virus type 1 upon primary infection. J. Virol. 67 6 (1993) 3345-3356
44. Zhang L., Diaz R.S., Ho D.D., Mosley J.W., Busch M.P., and Mayer A. Host-specific driving force in human immunodeficiency virus type 1 evolution in vivo. J. Virol. 71 3 (1997) 2555-2561
45. Zhu T., Mo H., Wang N., Nam D.S., Cao Y., Koup R.A., and Ho D.D. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 261 5125 (1993) 1179-1181